Study of OnabotulinumtoxinA (BOTOX) for platysma prominence

The company Allergan is commencing recruitment for the clinical trial of the A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence.

The condition is Platysma Prominence.

A new clinical trial is recruiting patients in the following locations: .

The trial officially began on the June 25, 2021 and is planned to complete on October 17, 2022.

The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence. Study doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 400 participants will be enrolled in the study in the United States and Canada. Participants will receive either intramuscular injections of onabotulinumtoxinA (BOTOX) or placebo. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic.

The link to the complete study profile:

Clinical Research News

Upcoming Clinical Trials